176 related articles for article (PubMed ID: 34273111)
1. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L
Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111
[TBL] [Abstract][Full Text] [Related]
2. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.
Simões AT; Gonçalves N; Koeppen A; Déglon N; Kügler S; Duarte CB; Pereira de Almeida L
Brain; 2012 Aug; 135(Pt 8):2428-39. PubMed ID: 22843411
[TBL] [Abstract][Full Text] [Related]
3. A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3.
Weber JJ; Golla M; Guaitoli G; Wanichawan P; Hayer SN; Hauser S; Krahl AC; Nagel M; Samer S; Aronica E; Carlson CR; Schöls L; Riess O; Gloeckner CJ; Nguyen HP; Hübener-Schmid J
Brain; 2017 May; 140(5):1280-1299. PubMed ID: 28334907
[TBL] [Abstract][Full Text] [Related]
4. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.
Watchon M; Yuan KC; Mackovski N; Svahn AJ; Cole NJ; Goldsbury C; Rinkwitz S; Becker TS; Nicholson GA; Laird AS
J Neurosci; 2017 Aug; 37(32):7782-7794. PubMed ID: 28687604
[TBL] [Abstract][Full Text] [Related]
5. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
[TBL] [Abstract][Full Text] [Related]
6. Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease.
Simões AT; Gonçalves N; Nobre RJ; Duarte CB; Pereira de Almeida L
Hum Mol Genet; 2014 Sep; 23(18):4932-44. PubMed ID: 24817574
[TBL] [Abstract][Full Text] [Related]
7. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
8. Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease.
Weber JJ; Haas E; Maringer Y; Hauser S; Casadei NLP; Chishti AH; Riess O; Hübener-Schmid J
Hum Mol Genet; 2020 Apr; 29(6):892-906. PubMed ID: 31960910
[TBL] [Abstract][Full Text] [Related]
9. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.
Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V
J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899
[TBL] [Abstract][Full Text] [Related]
10. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
Gonçalves N; Simões AT; Cunha RA; de Almeida LP
Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
[TBL] [Abstract][Full Text] [Related]
11. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3.
Toonen LJ; Schmidt I; Luijsterburg MS; van Attikum H; van Roon-Mom WM
Sci Rep; 2016 Oct; 6():35200. PubMed ID: 27731380
[TBL] [Abstract][Full Text] [Related]
13. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
14. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
15. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
Paulino R; Nóbrega C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
[TBL] [Abstract][Full Text] [Related]
16. KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.
Abeditashi M; Weber JJ; Pereira Sena P; Velic A; Kalimeri M; Incebacak Eltemur RD; Schmidt J; Hübener-Schmid J; Hauser S; Macek B; Riess O; Schmidt T
Cell Mol Life Sci; 2022 Jul; 79(8):401. PubMed ID: 35794401
[TBL] [Abstract][Full Text] [Related]
17. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
18. Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment.
Onofre I; Mendonça N; Lopes S; Nobre R; de Melo JB; Carreira IM; Januário C; Gonçalves AF; de Almeida LP
Sci Rep; 2016 Jun; 6():28220. PubMed ID: 27328712
[TBL] [Abstract][Full Text] [Related]
19. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.
Lin GY; Ma CY; Kuo LC; Hsieh BY; Wang H; Liu CS; Hsieh M
Metab Brain Dis; 2022 Aug; 37(6):2103-2120. PubMed ID: 35488942
[TBL] [Abstract][Full Text] [Related]
20. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
Rajamani K; Liu JW; Wu CH; Chiang IT; You DH; Lin SY; Hsieh DK; Lin SZ; Harn HJ; Chiou TW
Neuropharmacology; 2017 May; 117():434-446. PubMed ID: 28223212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
